Kathy Rooney joins Activx as VP, Corporate Planning and Administration

September 5, 2000

La Jolla, CA - Activx Biosciences, Inc. announced today that Kathy Rooney has joined Activx as Vice President for Corporate Planning and Administration. Kathy Rooney was Vice President, Administration, at Collateral Therapeutics, Inc. from 1996 to 2000. Before joining Collateral, Kathy was Director of Project Planning at Sequana Therapeutics, Inc. Kathy previously was the Director of Project Planning and Administration at Gensia Pharmaceuticals, Inc., coordinating the discovery, development and manufacturing of several novel drug candidates from preclinical research through the submission of New Drug Applications. It was at Gensia that Rooney first worked with Rob Hillman, Ph.D., the CEO of Activx, who was Vice President of Pharmaceutical and Delivery Systems Development at Gensia. "We are extraordinarily pleased that Kathy Rooney will be joining us at Activx. Her broad experience in the biotechnology industry will be of great value to us as we begin our work of building Activx into the world leader in proteomics" said Hillman. According to Hillman, Activx's proprietary technology is the first technology platform for activity-based proteomics, enabling the identification and analysis of changes in active proteins in different cell types and under different conditions. "Activx's technology goes straight to the central question of post-genomic biology - which protein activities are responsible for health and disease?" explained Hillman. Activx was founded in 2000 by Hillman and scientists Ben Cravatt, Ph.D., of The Scripps Research Institute and Jeffrey W. Smith, Ph.D., of the Burnham Institute.

<< back to News